UNSPSC 51333901: Quinagolide

This classification denotes an antipsychotic agent with the molecular formula C20H33N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80Q9QWN15M, chemically known as sulfamide, n,n-diethyl-n-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)-, (3-alpha,4a-alpha,10a-beta)-(+-)- but generally known as quinagolide, which bears US NIH Compound Identifier 55645. European Medicines Agency schedules Quinagolide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10199MIG.

UNSPSC 51333901 Quinagolide, a Commodity code, does not align with the state and local procurement activity currently tagged to it. The recent opportunities posted under this code — naloxone and drug deactivation systems procurement, a therapeutic pharmacy initiative RFI, and a multistate cooperative generic pharmaceuticals contract — involve naloxone, OTC products, and prescription fulfillment logistics, not quinagolide, a dopamine agonist pharmaceutical used in endocrinology. The mismatch suggests either a cataloging error in the source system or that this code sits upstream of narrower commodity classifications actually driving procurement. State and local issuing bodies posting under this code span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing groups (Minnesota Department of Administration / MMCAP).

Recent activity shows a mix of direct procurement and cooperative-purchasing vehicles. Seminole County issued an IFB (IFB60459723LAS, due July 26, 2023) seeking annual delivery of naloxone and drug deactivation systems with quarterly deliveries to a community health building. The Texas HHS Commission posted an RFI (HHS0017013, response deadline April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs. MMCAP, the Minnesota Multistate Cooperative Purchasing Alliance administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026 and performance penalties of $200 to $1,500 per violation. The geographic spread centers on Florida, Texas, and the Upper Midwest, with multistate reach through MMCAP's cooperating jurisdictions. Code activity shows little relevant procurement focused on quinagolide specifically.